China-based Jiangxi Jemincare Group (SHA: 603222) has announced receiving clinical trial approvals for six of its Category 1 chemical drugs in China and the United States, with indications spanning cancer, kidney diseases, and infectious diseases.
JMKX003801, approved for study in China for severe infections caused by Gram-negative bacteria, has demonstrated broad-spectrum antibiotic properties in pre-clinical studies and is expected to combat antibiotic resistance.
JMKX003142, a new-generation diuretic approved for study in China, has shown reduced side effects in research, potentially improving the quality of life for patients with kidney diseases.
JMKX003948, approved for study in renal cell carcinoma in China, features a distinct mechanism of action compared to tyrosine kinase inhibitors (TKI) and immunotherapies, showing significant efficacy in pre-clinical studies as a monotherapy or in combination with other treatments.
JMKX000197, approved for study in the US for non-muscle invasive bladder cancer that has failed BCG treatment, can modulate the immune system and cytokines, with pre-clinical studies showing significant anti-tumor effects in BCG-unresponsive animal models.
JMKX003002, a new-generation phosphorus-reducing agent approved for study in hyperphosphatemia in end-stage renal disease dialysis patients in the US, exhibits good oral compliance and high in vitro persistence. It is anticipated to persistently reduce blood phosphorus levels and enhance the quality of life for kidney disease patients.- Flcube.com
